Research consulting

Does the science behind the deal hold up?

Independent scientific due diligence for biotech, AI and other science-led investments. Know what is demonstrated, assumed and still unknown before capital is committed.

Aron Bijl, MSc. · Peer-reviewed researcher

INVESTMENT EVIDENCE NOTEScientific claim review

Claim strength

CONDITIONAL

Primary concern

EXTERNAL VALIDITYSource-linked · Human-reviewed
CHECK THE ASSUMPTION
48–72h standard scoped reviewsSource-linkedHuman-reviewedFrom €595

A polished deck is not evidence.

The commercial story may be coherent while the scientific case is not. Due diligence makes the gap visible before it becomes an expensive surprise.

Demonstrated
Findings supported by the available evidence.
Assumed
Necessary premises that have not yet been established.
Unknown
Open questions that could materially change the decision.
DECISION LEDGER

Evidence status

SUPPORTED
  1. Claim integrity
  2. Method quality
  3. Bias and reproducibility
  4. Decision impact
Judgement changes as the evidence is tested.
01

Claim integrity

What is actually being claimed, and does the cited evidence support that exact claim?

02

Method quality

Are the design, sample, controls and analysis strong enough for the conclusion being sold?

03

Bias and reproducibility

What depends on selective reporting, fragile assumptions or results that have not held up elsewhere?

04

Decision impact

Which findings change the investment case, and which uncertainties should become conditions or follow-up work?

Not more information. A better decision.

The deliverable is built around the question the investment committee actually needs answered.

Decision brief

A direct conclusion, calibrated to the strength of the evidence.

Evidence map

The strongest sources, conflicting findings and missing support.

Risk register

Assumptions, caveats and unresolved questions ranked by decision impact.

Debrief

A focused discussion of the findings and the next questions worth asking.

Research credentials, not borrowed authority.

I hold an MSc. in psychology and have authored peer-reviewed research. My work combines scientific method, evidence calibration and AI-assisted analysis, with the final judgement remaining human and explicit.

Sample page from a cited analysis of 3,793 language models
Sample: comparative analysis across 3,793 language models

Good fit

Investment committees, corporate development teams and technical leads evaluating science-led assets, claims or capabilities.

Clear boundary

Scientific and methodological input only. It is not clinical, regulatory, legal or financial advice.

Before you send the data room.

What is scientific due diligence?

An independent review of the scientific claims, methods and evidence behind an investment, partnership or acquisition. The output separates demonstrated results from assumptions and unresolved risks.

What can be delivered in 48–72 hours?

A tightly scoped review using available publications, technical materials and supplied documents. Broader evidence landscapes or large data rooms need a separate timeline.

What materials can you review?

Peer-reviewed papers, preprints, white papers, patents, protocols, technical reports, pitch materials and internal source libraries, subject to an agreed scope and confidentiality terms.

Is this regulatory, clinical, legal or financial advice?

No. The review is scientific and methodological input for your decision process. It does not replace specialist regulatory, clinical, legal or financial advice.

What does it cost?

Focused assignments start at €595 excluding VAT. Larger reviews are quoted after the decision, materials, depth and deadline are clear.

Put the investment question on the table.

Tell me what decision is being made, what evidence exists and when the answer is needed. I will reply with a proposed scope, price and delivery window.

Focused assignments from €595 excluding VAT.

Your information is used only to respond to this enquiry. See the privacy page.